arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Vera Therapeutics, Inc.

VERA

$33.03 ▼ -3.20 (-8.82%) at close

7 Visible periods

23 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Neutral

auto_awesome

Analytical Summary

Vera Therapeutics, Inc. demonstrates solid fundamentals with strength in Debt to Equity. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $2.1B

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -46.4% ↘

FCF / Share $-3.76 ↘

Trailing P/E —

Price / Book 3.5x

FCF Yield —

Debt / Equity 0.12

info Valuation on last close. End-of-day price, Sep 23, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-299.62M

↓ -96.9% —

FCF / Share Free cash flow per share

$-3.76

↓ -53.5% —

Long-Term Debt Long-term obligations

$74.84M

↑ +47.6% —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Financial Health ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	-69.5% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-22.2% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	32.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-37.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-96.9% Weak ↓ Weak Declining Year-over-year change in net income	-58.5% Weak ↓ Weak Declining Year-over-year change in net income	-7.8% Weak ↑ Weak Improving Year-over-year change in net income	-173.1% Weak Weak Year-over-year change in net income	38.9% Excellent Excellent Year-over-year change in net income	—	—
FCF Growth YoY (%)	-53.5% Weak ↓ Weak Declining Year-over-year change in free cash flow	-13.5% Weak ↑ Weak Improving Year-over-year change in free cash flow	15.2% Good Good Year-over-year change in free cash flow	-44.3% Weak Weak Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Effective Tax Rate (%) (%)	-0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
FCF / Net Income (x)	0.81x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.76x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.65x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-46.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-26.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-67.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-89.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-46.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	58.5% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-42.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-25.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-58.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-69.2% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-41.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-95.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-49.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-430%)	-26.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-276%)	-94.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-729%)	-115.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-872%)	-46.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-412%)	59.8% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+299%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Debt to Equity (x)	0.12x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-79%)	0.09x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-85%)	0.49x Good ↑ Good Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-18%)	0.32x Good ↑ Good Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-46%)	0.07x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-88%)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	—
Interest Coverage (x)	-46.95x Weak → Weak Stable Operating income divided by interest expense Optimal: > 5x	-25.13x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-30.43x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-91.64x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-1720.10x Weak Weak Operating income divided by interest expense Optimal: > 5x	-314.70x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-279.89M	$-41.96M	$4.20M	$-18.65M	$-74.75M	$-53.65M	—
Debt / EBITDA (x)	-0.24x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.30x Excellent → Excellent Stable Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.49x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.27x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.14x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-4.66	$-2.75	$-2.25	$-3.35	$-2.43	—	—
Free Cash Flow per Share (USD)	$-3.76	$-2.45	$-2.16	$-2.55	$-1.76	—	—
Book Value per Share (USD)	$9.41	$10.43	$2.38	$2.89	$5.18	—	—
Tangible Book Value per Share (USD)	$9.41	$10.43	$2.38	$2.89	$5.18	—	—
Basic Weighted Avg Shares (shares)	64.23M	55.33M	42.71M	26.57M	13.44M	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$675.43M	$625.85M	$149.72M	$100.10M	$74.85M	$51.85M	—
LT Debt (USD)	$74.84M	$50.69M	$49.88M	$24.81M	$4.92M	$0.00	—
Total Equity (USD)	$604.52M	$577.15M	$101.69M	$76.91M	$69.59M	$-89.35M	$-36.55M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Depreciation Expense (USD)	$468.00K	$105.00K	$21.00K	—	—	—	—
Net Income, GAAP (USD)	$-299.62M	$-152.15M	$-95.99M	$-89.06M	$-32.61M	$-53.41M	—
Operating Cash Flow (USD)	$-241.10M	$-134.68M	$-92.18M	$-67.60M	$-23.71M	$-34.81M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters

Vera Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare VERA with peers